Effect of Atractylodin on high fat diet-induced fatty liver disease
The escalating prevalence of metabolic diseases, driven by the rapid increase in obesity rates, necessitates effective therapeutic strategies. Insulin resistance and nonalcoholic fatty liver disease represent significant metabolic disorders. Atractylodin exhibits anti-inflammatory and antioxidant properties, suggesting potential hepatoprotective effects against acute liver damage. As therapeutic interventions for nonalcoholic steatohepatitis are lacking, this study aims to elucidate the pharmacological impact of Atractylodin on lipid and glucose metabolism. Overall design: Eight-week-old male C57BL/6N mice were given a high-fat diet (HFD) ad libitum for 12 weeks. After 8 weeks of HFD feeding, mice were administered Atractylodin (10 mg/kg body weight) or a vehicle. Atractylodin was orally administered five days per week. After 4 weeks of drug administration, the mice were sacrificed.